UCB sells UCB Internal Medicine to Paragon Partners
Mohnheim/ Frankfurt a. M. — UCB S.A. has sold its subsidiary UCB Innere Medizin to Paragon Partners. DC Advisory advised UCB S.A. on the transaction.
UCB Inn ere Medizin (“Internal Medicine”), which has been operating as an independent business unit of UCB since March 2016, has been successfully marketing drugs in the field of cardiovascular and respiratory diseases in Germany for many years and is mainly known among general practitioners and specialists in internal medicine.
In line with its global strategy, the sale of Internal Medicine will enable UCB to focus on its core business in neurology, immunology as well as bone diseases to provide the best solutions for people with severe chronic diseases.
Paragon Partners(“Paragon”) will acquire Internal Medicine and its entire staff of approximately 200 employees and will operate Internal Medicine as an independent company. Paragon intends to continue its successful business model and strategic orientation, as well as to further develop and expand its business. Internal Medicine will operate under a new name, which will be announced shortly after the transaction closes. The company’s headquarters will remain the “Creative Campus” in Monheim am Rhein.
“I am convinced that Paragon is the ideal choice to drive the development of internal medicine. I would like to thank the entire team for the work they have done at UCB and wish everyone every success in the new era as a completely independent organization,” said Johannes Leuchs, Head of Established Brands UCB. “We are grateful for UCB’s contribution to the success of internal medicine. Now we look forward to joining the Paragon family. This is an exciting opportunity for Internal Medicine and its employees,” added Karlheinz Gast, CEO of Internal Medicine. “We see great potential for Internal Medicine and look forward to the next stage,” confirmed Dr. Edin Hadzic, Managing Partner at Paragon. “We have confidence in Mr. Gast and his team and are excited to continue to grow the company together.”
Through its local presence in Europe, Asia and the US, DC Advisory was able to successfully orchestrate a selective auction process. “We are very pleased to have found a suitable partner for Internal Medicine and wish Karlheinz Gast and his team all the best for the next growth phase of Internal Medicine,” expressed Dr. Wolfgang Kazmierowski, Managing Director at DC Advisory.
Subject to antitrust clearance, the transaction is expected to be completed by the end of September 2018. Both parties have agreed not to disclose details of the transaction.
About DC Advisory
We advise our clients on all aspects of company acquisitions and sales. In addition, we provide ongoing support to company owners and managers in developing and implementing their business strategy to help their companies achieve optimal growth. Our extensive experience and industry knowledge, as well as our sound judgment, provide our clients with real competitive advantages. www.dcadvisory.com